Do insulin resistance and hepatic fat increase hepatic VLDL secretion and raise triglycerides, non-HDL cholesterol, and ApoB?

Insulin resistance and the accumulation of hepatic fat are major physiological drivers of systemic lipid imbalances, orchestrating a cascade that alters lipoprotein metabolism.

Mechanistic pathway of VLDL overproduction

• Blunted insulin suppression: Under healthy conditions, insulin acutely suppresses the hepatic secretion of very-low-density lipoprotein (VLDL) and apolipoprotein B-100 (ApoB-100). In insulin-resistant states, this acute inhibitory control is blunted, resulting in sustained, elevated VLDL particle production.
• Substrate-driven stabilization: Hepatic fat accumulation provides an abundant intracellular triglyceride pool. This lipid abundance stimulates microsomal triglyceride transfer protein (MTP) activity, which lipidates nascent ApoB-100 in the endoplasmic reticulum. This lipidation protects ApoB-100 from proteasomal degradation, allowing a higher fraction of particles to be successfully assembled and secreted as VLDL.

Impact on circulating lipid biomarkers

• Elevation of plasma triglycerides: VLDL is the primary carrier of fasting plasma triglycerides. Consequently, the accelerated secretion of triglyceride-rich VLDL particles from the liver directly drives systemic hypertriglyceridemia.
• Increased ApoB and non-HDL cholesterol: Because each VLDL particle contains precisely one ApoB-100 molecule, increased hepatic VLDL secretion directly elevates total circulating ApoB levels.
• Remnant accumulation: Following secretion, intravascular lipolysis and remodeling convert these VLDL particles into highly atherogenic intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) remnants. This increase in the entire spectrum of ApoB-containing lipoproteins is reflected in a corresponding rise in non-HDL cholesterol.

Bottom line

• Bottom line: Insulin resistance and hepatic fat accumulation operate synergistically to drive hepatic VLDL overproduction. This dual pathology directly causes elevations in plasma triglycerides, ApoB, and non-HDL cholesterol, representing the central pathway of atherogenic dyslipidemia.